Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03322995 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

Study acronym: PANC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Aug 1, 2026 to Jun 1, 2027 Completion date: Aug 1, 2027 to Jun 1, 2032v9 Show 1 more changeShow less
    • Completion date: Aug 1, 2027 to Jun 1, 2032
  2. Re-verified, no change to tracked fieldsv8
  3. Primary completion date: Aug 1, 2023 to Aug 1, 2026 Completion date: Aug 1, 2024 to Aug 1, 2027 · Site contact updated · Study title shortened, about 9 wordsv7 Show 3 more changesShow less
    • Completion date: Aug 1, 2024 to Aug 1, 2027
    • Site contact updated
    • Study title shortened, about 9 words

    See this version in full on ClinicalTrials.gov ↗

  4. Re-verified, no change to tracked fieldsv6
  5. Primary completion date: Aug 1, 2022 to Aug 1, 2023 Eligibility criteria expanded, about 97 wordsv5 Show 1 more changeShow less
    • Eligibility criteria expanded, about 97 words

    See this version in full on ClinicalTrials.gov ↗

Show 3 earlier versionsHide 3 earlier versions
  1. Primary endpoint revised Eligibility criteria expanded, about 16 words · Secondary endpoints revised (2) · Study description expanded, about 14 words · 1 morev4 Show 4 more changesShow less
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints revised (2)
    • Study description expanded, about 14 words
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jul 1, 2021 to Aug 1, 2022 · Start date changed from estimate of Nov 1, 2017 to Jun 21, 2018 · Primary endpoints: 2 to 1 · 9 morev2 Show 12 more changesShow less
    • Primary completion date: Jul 1, 2021 to Aug 1, 2022
    • Start date changed from estimate of Nov 1, 2017 to Jun 21, 2018
    • Primary endpoints: 2 to 1
    • Enrollment target: 154 to 125
    • Study sites: 0 to 1
    • Completion date: Jul 1, 2023 to Aug 1, 2024
    • Interventions: Chemoradiation (Radiation), Chemotherapy (Drug), Initial molecular profile-directed therapy (Other), Surgery (Procedure) to Chemoradiation (Radiation), First-line Chemotherapy (Drug), Second-line Chemotherapy (Drug)
    • Eligibility criteria shortened, about 141 words
    • Secondary endpoints: 4 to 2
    • Study description shortened, about 396 words
    • Study title expanded, about 9 words
    • Study arms: 4 to 3

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.
Trial Details
NCT Number NCT03322995
Lead Sponsor Medical College of Wisconsin
Conditions Pancreatic Cancer
Enrollment 125 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov